Risk of hepatocellular carcinoma in cirrhotic hepatitis <scp>B</scp> virus patients during nucleoside/nucleotide analog therapy

Abstract

LC status was the significant risk factor of development of HCC during NA therapy. However, none of the patients who showed HBsAg seroclearance developed HCC. The ultimate goal of therapy for reduced risk of HCC may be HBsAg seroclearance.